Sites of CRPC metastases appropriate for R-223Sites of CRPC metastases appropriate for R-223Describe the type of patient with metastatic castration-resistant prostate cancer (CRPC) for whom you would consider administering radium-223 (R-223).
Dorff TB et al. Radium 223: How can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book 2015;35:e270-3. Abstract El-Amm J et al. Radium-223 for the treatment of castration-resistant prostate cancer. Onco Targets Ther 2015;8:1103-9. Abstract Hoskin P et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397-406. Abstract Humm JL et al. Radium-223 in the treatment of osteoblastic metastases: A critical clinical review. Int J Radiat Oncol Biol Phys 2015;91(5):898-906. Abstract Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23. Abstract Sartor O et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15(7):738-46. Abstract |